Hepatitis C virus (HCV) is a major cause of chronic hepatitis worldwide. Scavenger receptor
class B type I (SR‐BI) has been shown to bind HCV envelope glycoprotein E2, participate in …

The tight junction protein claudin‐1 (CLDN1) has been shown to be essential for hepatitis C
virus (HCV) entry—the first step of viral infection. Due to the lack of neutralizing anti‐CLDN1 …

BACKGROUND & AIMS: Hepatitis C virus (HCV) infection is a challenge to prevent and treat
because of the rapid development of drug resistance and escape. Viral entry is required for …

BACKGROUND AND AIMS: ITX 5061 is a clinical stage small molecule compound that
promotes high-density lipoprotein (HDL) levels in animals and patients by targeting the …

Hepatitis C virus (HCV) is transmitted between hepatocytes via classical cell entry but also
uses direct cell-cell transfer to infect neighboring hepatocytes. Viral cell-cell transmission has …

End-stage liver disease caused by chronic hepatitis C virus (HCV) infection is a leading
cause for liver transplantation (LT). Due to viral evasion from host immune responses and the …

BK virus–associated nephropathy (BKVAN) causes renal allograft dysfunction. The current
management of BKVAN relies on pre-emptive adaptation of immunosuppression according to …

Transplant recipients, who receive therapeutic immunosuppression to prevent graft rejection,
are characterized by high coronavirus disease 2019 (COVID-19)–related mortality and …

BK virus (BKV) replication occurs frequently in kidney transplant recipients (KTR), potentially
leading to BKV‐associated nephropathy (BKVAN) and graft loss. Patients with high titers of …

BACKGROUND Previous studies have reported that lung transplant recipients (LTR) develop
a poor response to two doses of COVID-19 vaccine, but data regarding the third dose are …